Cargando…
Competition law and pricing among biologic drugs: the case of VEGF therapy for retinal diseases
Neovascular age-related macular degeneration (AMD) is a progressive eye disease and is a leading cause of vision loss in the Western world. Vascular endothelial growth factor inhibitors have become a mainstay of treatment for this disease. Currently, treatment options include three originator biolog...
Autores principales: | Van de Wiele, Victor L, Hammer, Maximilian, Parikh, Ravi, Feldman, William B, Sarpatwari, Ameet, Kesselheim, Aaron S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8863367/ https://www.ncbi.nlm.nih.gov/pubmed/35211322 http://dx.doi.org/10.1093/jlb/lsac001 |
Ejemplares similares
-
Competition and price among brand-name drugs in the same class: A systematic review of the evidence
por: Sarpatwari, Ameet, et al.
Publicado: (2019) -
Outcomes of the 340B Drug Pricing Program: A Scoping Review
por: Knox, Ryan P., et al.
Publicado: (2023) -
The Case for Reforming Drug Naming: Should Brand Name Trademark Protections Expire upon Generic Entry?
por: Sarpatwari, Ameet, et al.
Publicado: (2016) -
Paying Physicians to Prescribe Generic Drugs and Follow-On Biologics in the United States
por: Sarpatwari, Ameet, et al.
Publicado: (2015) -
Regulatory Solutions to the Problem of High Generic Drug Costs
por: Luo, Jing, et al.
Publicado: (2015)